Solid Tumor
Conditions
Keywords
cancer, imaging agent, HSP90
Brief summary
HS-196 is near infrared red (NIR)-tethered HSP90 inhibitor for clinical imaging of selective tumor binding. HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain connected by a linker to a contrast agent (near infrared (NIR) dye) that can be used for imaging. HS-196 can freely enter tumor cells to selectively bind Hsp90. Due to the the NIR dye, HS-196 accumulation in the malignant cells allows for specific visualization of tumors within the body.
Detailed description
The product to be tested under this IND, HS-196, is a tumor imaging agent. Hsp90 (heat shock protein 90) is a chaperone protein that aids in the folding, stabilization, and degradation of cellular proteins and is found in virtually all living organisms. Cancer cells in particular have high expression of Hsp90. Hsp90 has three structural domains including an N-terminal domain that contains an ATP binding site. Small molecule inhibitors of HSP90 (Hsp90i) can selectively and competitively to the Hsp90 ATP binding domain. HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain connected by a linker to a contrast agent (near infrared (NIR) dye) that can be used for imaging. HS-196 can freely enter tumor cells to selectively bind Hsp90. Due to the the NIR dye, HS-196 accumulation in the malignant cells allows for specific visualization of tumors within the body. HS-196 will be used in this investigation for the imaging of solid tumors The objectives of the study are to determine the dose of HS-196 that achieves the greatest ratio of tumor to normal tissue fluorescence in patients with malignancy, the safety of HS-196 administration in patients with malignancy, the average radiant efficiency in resected tumors following HS-196 administration, the localization of the HS-196 by microscopy of tumor slices, and the PK metrics of HS-196 when administered to patients.
Interventions
DRUGHS-196
HS-196 will be administered intravenously as a single dose
Sponsors
Herbert Lyerly
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
For Dose escalation and recommended dose phases: * Diagnosis of a solid malignancy, stage I-IV, with planned surgical resection or biopsy. For Expansion phase: * Patients with mammographically detected breast nodules with planned surgical resection or biopsy. For All phases: * ECOG 0 or 1 * Estimated life expectancy \> 3 months * Age ≥ 18 years * Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR \<1.5, PTT \<1.5X ULN * Adequate renal and hepatic function, with serum creatinine \< 1.5 mg/dL, bilirubin \< 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal or if liver metastases are present \< 5 x upper limit of normal. * Female patients must be of non-child-bearing potential or use effective contraception, e.g., use of oral contraceptives with an additional barrier method (since the study drug may impair the effectiveness of oral contraceptives), double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera, partner vasectomy, total abstinence, and willing to continue the effective contraception method for 30 days after the last dose of study drug; * Ability to understand and provide signed informed consent that fulfills Institutional Review Board's guidelines. * Ability to return to Duke University Medical Center for adequate follow-up, as required by this protocol.
Exclusion criteria
* Serious chronic or acute illness considered by the P.I. to constitute an unwarranted high risk for investigational drug treatment. * Medical or psychological impediment to probable compliance with the protocol. * Asthma under medical management * Uncontrolled high blood pressure * Presence of a known active acute or chronic infection including HIV or viral hepatitis (Hepatitis B and C)). * Pregnant or nursing women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fluorescence | 1 day | Ratio of tumor to normal tissue fluorescence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of AEs | 1 month | Safety of HS-196 administration in patients with malignancy |
| Radiant Efficiency | 1 day | The average radiant efficiency in resected tumors following HS-196 administration. |
| HS-196 Localization | 1 day | Localization of the HS-196 by microscopy of tumor slices. |
| Maximum Plasma concentration Cmax | 1 week | PK metrics of HS-196 when administered IV to patients |
| Area Under the Curve AUC | 1 week | PK metrics of HS-196 when administered IV to patients |
Countries
United States
Outcome results
None listed